The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 1, 2004, Pages 56-61

  Serhat Inaloz, H ^a   Evereklioglu, C ^a   Unal, B ^a   Kirtak, N ^a   Eralp, A ^a   Inaloz, S S ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Beh et's syndrome; E selectin; Endoglin; Immunohistochemistry; P selectin; Skin pathergy reaction

Indexed keywords

ACUTE PHASE PROTEIN; BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; ENDOGLIN; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE DISTRIBUTION; ARTICLE; BEHCET DISEASE; CELL COUNT; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMIS; DISEASE ACTIVITY; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; ETHNOLOGY; FEMALE; FOREARM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; MALE; MEDICAL ASSESSMENT; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; PUNCH BIOPSY; SEX DIFFERENCE; SKIN APPENDAGE; SKIN BLOOD VESSEL; SKIN DEFECT; SKIN MANIFESTATION; SKIN TEST; VASCULAR ENDOTHELIUM;

ADULT; BEHCET SYNDROME; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; SKIN; SKIN TESTS; STATISTICS, NONPARAMETRIC;

EID: 0742272142     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00547.x     Document Type: Article

References (38)

1. Gul A, Esin S, Dilsen N et al. Immunohistology of skin pathergy reaction in Behçet's disease. Br J Dermatol 1995; 132: 901-907.
2. Rizzi R, Bruno S, Dammacco R. Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997; 27: 225-232.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284-1291.
4. Blobner F. Zur rezidivierenden Hypopyon-Iritis. Z Augenheilk 1937; 91: 129-139.
5. Haim S, Sobel JD, Friedman-Birnbaum R, Lichtig C. Histological and direct immunofluorescence study of cutaneous hyperreactivity in Behçet's disease. Br J Dermatol 1976; 95: 631-636.
6. Haim S. The pathogenesis of lesions in Behçet's disease. Dermatologica 1979; 158: 31-37.
7. Lehner T, Fortune F, Lavery E, Studd M. Recent advances in T-cell immunoregulation and in the microbial causes of Behçet's disease. In: O'Duffy JD, Kokmen E, editors. Behçet's Disease: Basic and Clinical Aspects. Marcel Dekker, New York, 1991: 463-473.
8. Jorizzo JL, Solomon AR, Cavallo T. Behçet's syndrome: immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up. Arch Pathol Lab Med 1985; 109: 747-751.
9. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287.
10. Palabrica T, Lobb R, Furie BC et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
11. van de Kerkhof PC, Rulo HF, van Pelt JP et al. Expression of endoglin in the transition between psoriatic uninvolved and involved skin. Acta Derm Venereol 1998; 78: 19-21.
12. Haznedaroglu E, Karaaslan Y, Buyukasik Y et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis 2000; 59: 61-63.
13. Kosar A, Haznedaroglu S, Karaaslan Y et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int 1999; 19: 11-14.
14. Senturk T, Aydintug O, Kuzu I et al. Adhesion molecule expression in erythema nodosum-like lesions in Behçet's disease. A histopathological and immunohistochemical study. Rheumatol Int 1998; 18: 51-57.
15. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
16. Friedman Birnbaum R, Bergman R, Aizen E. Sensitivity and specificity of pathergy test results in Israeli patients with Behçet's disease. Cutis 1990; 45: 261-264.
17. Dilsen N, Konice M, Aral O, Aykut S. Standardization and evaluation of the skin pathergy test in Behçet's disease and controls. In: Lehner T, Barners CH, editors. Recent Advances in Behçet's Disease. London, Royal Society of Medicine Services, 1986, 169-172.
18. Evereklioglu C, Yurekli M, Er H et al. Increased plasma adrenomedullin levels in patients with Behçet's disease. Dermatology 2000; 201: 312-315.
19. Behçet H. Uber rezidivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157.
20. Evereklioglu C, Inaloz HS, Kirtak N et al. Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. Br J Dermatol 2002; 147: 331-336.
21. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behçet's syndrome in Hawaii. With particular references to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J 1975; 34: 244-246.
22. Evereklioglu C, Er H. Increased corneal thickness in active Behçet's disease. Eur J Ophthalmol 2002; 12: 24-29.
23. Evereklioglu C, Cokkeser Y, Doganay S et al. Audio-vestibular evaluation in patients with Behçet's disease. J Laryngol Otol 2001; 115: 704-708.
24. Gunen H, Evereklioglu C, Kosar F et al. Thoracic involvement in Behçet's disease and its correlation with multiple parameters. Lung 2000; 178: 161-170.
25. Evereklioglu C, Ozbek E, Er H et al. Urinary adrenomedullin levels are increased and correlated with plasma concentrations in patients with Behçet's syndrome. Int J Urol 2002; 9: 296-303.
26. Turkoz Y, Evereklioglu C, Mehmet N et al. Plasma malondialdehyde levels in Behçet's disease with or without ocular involvement. Adv Reprod 2000; 4: 31-36.
27. Evereklioglu C, Turkoz Y, Er H et al. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46: 50-54.
28. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediat Inflamm 2002; 11: 87-93.
29. Jorizzo JL, Hudson RD, Schmalstieg FC et al. Behçet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol 1984; 10: 205-214.
30. Erkilic K, Evereklioglu C, Cekmen M et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations. Mediat Inflamm 2003; 12: 107-116.
31. Schmitz-Huebner U, Knop J. Evidence for an endothelial dysfunction in association with Behçet's disease. Thromb Res Suppl 1984; 34: 277-285.
32. Haznedaroglu IC, Ozdemir O, Ozcebe O et al. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease. Thromb Haemost 1996; 75: 974-975.
33. Haznedaroglu IC, Ozcebe O, Ozdemir O et al. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Intern Med 1996; 240: 181-187.
34. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 1998; 18: 2701-2710.
35. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 1998; 18: 1485-1500.
36. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neovascularization. Anticancer Res 1998; 18: 3621-3628.
37. Mould TL, Roberts-Thomson PJ. Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 2000; 18: 195-200.
38. Sullu Y, Senturk N, Yildiz L et al. Bcl-2 expression in skin pathergy reaction of Behçet's disease. Dermatology 2001; 202: